secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2021-09-13T23:59:59+00:00
Accession:  0001193125-21-270953
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 4.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience appoints Emma Reeve to Board, changes auditor to BDO after reverse merger
--------------------------------------------------------------------------------

- Emma Reeve appointed Class III director and Audit Committee Chair, effective Sept 8, 2021.
- Reeve brings experience from Constellation Pharmaceuticals (CFO, oversaw $1.7B sale) and board seats at PTC Therapeutics, Editas Medicine.
- Auditor changed: Ernst & Young dismissed, BDO engaged as independent auditor following reverse merger with Old Aadi; no disagreements or reportable events.
- Company highlights upcoming PDUFA target action date of Nov 26, 2021 for FYARRO (nab-sirolimus) in PEComa.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312521270953/0001193125-21-270953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312521270953/d138836d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-270953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer